It was reported that the PSMA-617 ligand in the form of [177Lu]Lu-PSMA-617 has a stronger PSMA-binding affinity, is more internalised into the target organ, has a higher tumour-to-background ratio at late time points and is more rapidly excreted via the kidneys than [68Ga]Ga-PSMA-11, marking its significant advantage. This evidence concerns the gene FOLH1 and neoplasm.